{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:21:36Z","timestamp":1763036496074},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.clinthera.2010.03.019","type":"journal-article","created":{"date-parts":[[2010,4,30]],"date-time":"2010-04-30T08:57:25Z","timestamp":1272617845000},"page":"717-728","source":"Crossref","is-referenced-by-count":19,"title":["A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective"],"prefix":"10.1016","volume":"32","author":[{"given":"Mark","family":"Nuijten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.03.019_bib1","series-title":"Harrison's Principles of Internal Medicine","first-page":"2409","article-title":"Multiple sclerosis and other demyelinating diseases","author":"Hauser","year":"1998"},{"key":"10.1016\/j.clinthera.2010.03.019_bib2","series-title":"Harrison's Principles of Internal Medicine","first-page":"2415","year":"1998"},{"key":"10.1016\/j.clinthera.2010.03.019_bib3","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2010.03.019_bib4","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/brain\/112.6.1419","article-title":"The natural history of multiple sclerosis: A geographically-based study. 2. Predictive value of the early clinical course","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"key":"10.1016\/j.clinthera.2010.03.019_bib5","first-page":"273","article-title":"Neuroimaging evaluation in multiple sclerosis","volume":"48","author":"Rieumont","year":"1993","journal-title":"Am Fam Physician"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2010.03.019_bib6","doi-asserted-by":"crossref","first-page":"S218","DOI":"10.1002\/ana.410360809","article-title":"The use and misuse of statistics for epidemiological studies of multiple sclerosis","volume":"36","author":"Hibberd","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2010.03.019_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2710.1996.tb01139.x","article-title":"Therapeutic advances: Beta-interferon for multiple sclerosis","volume":"21","author":"Clark","year":"1996","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2010.03.019_bib8","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/archneur.1989.00520460093019","article-title":"Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials","volume":"46","author":"Goodkin","year":"1989","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2010.03.019_bib9","series-title":"Oxford Textbook ofMedicine","author":"Weatherall","year":"1987"},{"key":"10.1016\/j.clinthera.2010.03.019_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0733-8619(18)30064-1","article-title":"The natural history of multiple sclerosis","volume":"13","author":"Weinshenker","year":"1995","journal-title":"Neurol Clin"},{"key":"10.1016\/j.clinthera.2010.03.019_bib11","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/archneur.1992.00530360035014","article-title":"Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis","volume":"49","author":"Rudick","year":"1992","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2010.03.019_bib12","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis [published correction appears in Lancet. 1999;353:678]","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2010.03.019_bib13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2010.03.019_bib14","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicenter randomised trial of interferon beta-1b in treatment of sec ondary progressive multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2010.03.019_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00004356-199209000-00004","article-title":"Economic status of families living with multiple sclerosis","volume":"15","author":"Catanzaro","year":"1992","journal-title":"Int J Rehabil Res"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2010.03.019_bib16","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1007\/s10198-006-0384-8","article-title":"Costs and quality of life of multiple sclerosis in Germany","volume":"7","author":"Kobelt","year":"2006","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.clinthera.2010.03.019_bib17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1749-6632.1984.tb14819.x","article-title":"The National Multiple Sclerosis Survey. Background and economic impact","volume":"436","author":"Weinfeld","year":"1984","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinthera.2010.03.019_bib18","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1212\/WNL.46.6.1613","article-title":"Meta-analysis of the placebo-treated groups in clinical trials of progressive MS","volume":"46","author":"Weinshenker","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2010.03.019_bib19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/archneur.1982.00510160062016","article-title":"The role of disease and demographic factors in the employment of patients with multiple sclerosis","volume":"39","author":"LaRocca","year":"1982","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2010.03.019_bib20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1749-6632.1965.tb20234.x","article-title":"Prognostic criteria in multiple sclerosis","volume":"122","author":"Bauer","year":"1965","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinthera.2010.03.019_bib21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/jnnp.53.5.388","article-title":"Multivariate analyses of factors associated with unemployment in people with multiple sclerosis","volume":"53","author":"Gr\u00f8nning","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2010.03.019_bib22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/00019053-199813050-00013","article-title":"Economic evaluation of multiple sclerosis in the UK, Germany and France","volume":"13","author":"Murphy","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2010.03.019_bib23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.18553\/jmcp.2009.15.7.543","article-title":"Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis","volume":"15","author":"Goldberg","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.clinthera.2010.03.019_bib24_1","unstructured":"IQWiG (Institute for Quality and Efficiency in Health Care). Methods for assessment of the relation of benefit to costs in the German statutory health care system-version 2.0."},{"key":"10.1016\/j.clinthera.2010.03.019_bib25","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1177\/1352458508089361","article-title":"Factors associated with the risk of secondary progression in multiple sclerosis","volume":"14","author":"Koch","year":"2008","journal-title":"Mult Scler"},{"key":"10.1016\/j.clinthera.2010.03.019_bib26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/ana.21102","article-title":"New natural history ofinterferonbeta-treated relapsing multiple sclerosis","volume":"61","author":"Trojano","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2010.03.019_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/archneur.1996.00550040093018","article-title":"Long-term and short-term outcome of multiple sclerosis: A 3-year follow-up study","volume":"53","author":"Weinshenker","year":"1996","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2010.03.019_bib28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1524-4733.2007.00301.x","article-title":"German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus","volume":"11","author":"Grafvon der Schulenburg","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2010.03.019_bib29","first-page":"1628","article-title":"PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS [published correction appears in Neurology. 2001; 57:1146]","volume":"56","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2010.03.019_bib30","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/01.WNL.0000034080.43681.DA","article-title":"Randomized, comparative study of interferon-beta-1a treatment regimens in MS: The EVIDENCE Trial","volume":"59","author":"Panitch","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2010.03.019_bib31","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1212\/WNL.53.4.679","article-title":"Evidence of interferon beta-1a dose response in relapsing remitting MS: The OWIMS Study","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2010.03.019_bib32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO;2-P","article-title":"Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-beta-1a in relapsing remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta-1a Subcutaneously in Multiple Sclerosis","volume":"46","author":"Li","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2010.03.019_bib33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis [published correction appears in Ann Neurol. 1996;40:480]","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2010.03.019_bib34","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1212\/01.WNL.0000032256.35561.D6","article-title":"A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS","volume":"59","author":"Clanet","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2010.03.019_bib35","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","article-title":"Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial","volume":"45","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2010.03.019_bib36","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1212\/WNL.43.4.662","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","author":"Paty","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2010.03.019_bib37","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results ofa phase III multicenter, double-blind placebo-controlled trial","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2010.03.019_bib38","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.64","article-title":"European\/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging\u2014measured disease activity and burden in patients with relapsing multiple sclerosis","volume":"49","author":"Comi","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2010.03.019_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1472-6963-3-17","article-title":"Cost of managing an episode of relapse in multiple sclerosis in the United States","volume":"3","author":"O'Brien","year":"2003","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clinthera.2010.03.019_bib40_1","unstructured":"Germany annual inflation rates."},{"key":"10.1016\/j.clinthera.2010.03.019_bib41","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta2040","article-title":"A cost-utility analysis of interferon beta for multiple sclerosis","volume":"2","author":"Parkin","year":"1998","journal-title":"Health Technol Asssess"},{"key":"10.1016\/j.clinthera.2010.03.019_bib42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1524-4733.2002.51052.x","article-title":"Costeffectiveness analysis of interferon beta in multiple sclerosis: A Markov process analysis","volume":"5","author":"Nuijten","year":"2002","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2010.03.019_bib43","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/BF00920623","article-title":"Prediction of outcome in multiple sclerosis based on multivariate models","volume":"241","author":"Runmarker","year":"1994","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2010.03.019_bib44_1","unstructured":"Leitlinien der DGN 2008. Diagnostik and Therapie der Multiplen Sklerose."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810001232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810001232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:15:51Z","timestamp":1635293751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810001232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0149291810001232"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.03.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}